Bin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bin Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexander McCampbell
Biogen Idec, Boston, Massachusetts, USA
1 shared publication Amy J. Wegener
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA
1 shared publication- Amy Setnicka
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA
1 shared publication - Brandon J. Farley
Biogen, Inc., Cambridge, Massachusetts, USA
1 shared publication - C. Frank Bennett
Ionis Pharmaceuticals, Carlsbad, CA 92010, USA
1 shared publication Danielle L. Graham
Biogen, Inc., Cambridge, Massachusetts, USA
1 shared publication
Latest Publications
- 16 July 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (8) , 3558-3567
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.
- 16 July 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (8) , 3558-3567
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.